A comprehensive analysis of Fitbit data reveals significant declines in daily step counts and exercise frequency among people taking GLP-1 receptor agonist medications, according to recent research. This pattern emerged despite these patients achieving their weight loss goals, presenting an important epidemiological finding for the millions using these popular medications. The Centers for Disease Control and Prevention recommends adults maintain at least 150 minutes of moderate-intensity aerobic activity weekly to support cardiovascular health and overall wellness. The observed reduction in physical activity among GLP-1 users suggests that weight loss alone may not automatically translate to increased movement or exercise engagement. This finding warrants further investigation into the mechanisms underlying reduced activity levels and potential interventions to encourage continued physical activity during pharmacological weight loss treatment. Read the full article on GMJ Newsroom.
Was this article helpful?
